Biotech Pre-Market Movers: AEMD, VEEA Surge; LGVN, ALMU Slide

Aethlon Medical (AEMD) shares rose 385% after announcing an all-stock merger with North Immunology and an $180 million private placement for NOR-101. The stock traded at $6.94, up from $1.43 the prior close, within a 52-week range of $1.41-$41.50.

Aethlon Medical (AEMD) rose 390% after announcing a merger with North Immunology, raising $180M. Metalsource Mining (MSM) reported high-grade silver intercepts. VisionWave (VWAV) filed a patent for an AI counter-drone system.

Aethlon Medical (AEMD) stock surged 393% after announcing a merger with North Immunology, a biotech developing treatments for immune and inflammatory diseases. The all-stock deal includes a $180M private placement and aims to advance NOR-101, a bispecific antibody for atopic dermatitis. The combined company will trade on Nasdaq under NRTX, with Aethlon shareholders owning 4.75% post-merger.

Aethlon Medical (AEMD) shares surged over 470% after announcing a merger with North Immunology and a $180M private placement. The combined company will focus on NOR-101, a bispecific antibody for atopic dermatitis, with Phase 1a trials expected in Q1 2027. Post-merger, the company will trade as NRTX on Nasdaq.

Aethlon Medical (AEMD) surged 346% premarket after announcing an all-stock merger with North Immunology, expected to close in Q1 2027. AEMD's P/S ratio is near zero, reflecting market skepticism. The combined entity, North Immunology Inc. (NRTX), is valued at $346.5M. AEMD's GF Score is 19/100, indicating weak financial health.

Aethlon Medical (NASDAQ:AEMD) shares surged over 400% in premarket trading after announcing a merger with North Immunology. The all-stock deal includes $180M in financing from investors. The combined entity will trade as NRTX on Nasdaq. North Immunology develops bispecific antibodies for immune diseases, with NOR-101 in development for atopic dermatitis.